Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

Small Cell Lung Cancer Clinical Trial

Official title:

A Phase Ⅱ Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02171325
• Other study ID #: CTONG1402
• Status: Recruiting
• Phase: Phase 2
• Start date: June 2014
• Est. completion date: June 2021

Study information

• Verified date: February 2021
• Source: Guangdong Association of Clinical Trials
• Contact: ying cheng, doctor
• Phone: 86-43185871902
• Email: jl.cheng[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to identify the appropriate dose of irinotecan by dose escalation(dose climbing) test. The study would provide rationale for regimen decision in a future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be selected as therapeutic drugs.

Description:

To determine the Maximum Tolerated Dose (MTD) and Limiting Toxicity (DLTs) of irinotecan in patients with extensive stage small cell lung cancer treated with irinotecan plus cisplatin

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: June 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age 18 to 65 years, male and female

2. Histologically or cytologically confirmed extensive stage .small cell lung cancer(SCLC )(except metastases only as pleural effusion)

3. No prior chemotherapy

4. Metastatic lesion had been treated more than 14 days by palliative radiation therapy or surgery

5. With measurable tumor lesions (Non-irradiated parts),(RECIST 1.1: Without radiotherapy ,the longest diameter is more than 10mm by CT or MRI ,except that lymph nodes need short diameter need more then 15mm, and the lesions can be accurately evaluated repeatedly measurable)

6. Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1

7. Expected survival = 3months

8. Marrow,kidney, liver,heart and lung are well -functioning,and absolute count of

• absolute neutrophil coun(ANC) = 2.0 × 109 / L

• blood platelet(PLT) = 100 × 109 / L

• Hb= 90g / L

• conjugative bilirubin(CB)= upper limit of normal(ULN) × 1.5

• Aspartate transaminase(AST )(glutamic oxalacetic transaminase,GOT): = upper limit of normal(ULN )× 2.5

• Alanine aminotransferase(ALT)(Glutamate Pyruvate Transaminase,GPT): = ULN × 2.5

• Serum creatinine: = ULN or calculated creatinine clearance= 60 ml / min

• (PT INR) = ULN × 1.5

• ECG: no abnormalities in need of treatment

9. No pregnancy or no pregnancy demand at the end of the study within six months

10. Must provide written informed consent.

Exclusion Criteria:

1. Patient have platinum compounds allergy history

2. Patient with active ulcer disease or chronic enteritis patients

3. Primary lesion(s) has (have) been treated by Surgery or radiation

4. Patient had received Immune drugs treatment for anti-lung cancer indications or anti-cancer Chinese traditional medicine treatment within two weeks

5. Patients with interstitial pneumonia or pulmonary fibrosis

6. Brain metastasis requiring treatment

7. Patient with bronchus or bronchial stenosis or blockage and superior vena cava syndrome caused by serious invasion

8. Patients with severe infections, severe abnormal secretion of (Anti Diuretic Hormone,ADH) syndrome, poorly controlled diabetes, severe complications requiring treatment vena cava syndrome

9. Severe cardiovascular disease: hypertension that medical treatment can not be controlled , unstable angina, myocardial infarction within the last June a history of congestive heart failure> 3 (NYHA) and severe arrhythmia

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Intervention

Drug:
• irinotecan
60 mg/m2?65mg/m2?70mg/m2?75mg/m2?80mg/m2?85mg/m2?90mg/m2?95mg/m2?100mg/m2

Locations

Country	Name	City	State
China	Jilin cancer hospital	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Guangdong Association of Clinical Trials

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Limiting Toxicity (DLT )in the irinotecan		up to 18 weeks
Secondary	Maximum Tolerated Dose(MTD)in the irinotecan		up to 18weeks